Recent Updates
Recently added Catalysts

Darbepoetin alpha

Phase 2

Hematological Malignancies | Small molecule | Oncology |Amgen Inc.|Last Updated: Jan 11, 2010

Target and mechanism

ModalitySmall molecule

Also known as Darbepoetin alpha (Aranesp)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment125

FDA Designations

No designations recorded

Clinical trial landscape

Darbepoetin alpha · 1 trial · 1 indication

Phase 2 1
NCT00557817Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)Hematological Malignancies
COMPLETED125 Analytics
PHASE2COMPLETED
Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
Hematological MalignanciesUnlock trial analytics

Study Endpoints

Primary Endpoints

Median time to achieve hemoglobin (Hb) level > 13 g/dL in each arm.
126 days after hematocrit (HCT)
Proportion of complete correctors (i.e. patients reaching Hb > 13 g/dL) before day 126 in each arm.
126 days after HCT

Secondary Endpoints

Median time to increase Hb level by > 2 g/dL in each arm.
126 days after HCT
Proportion of responders (i.e. patients increasing Hb by > 2 g/dL) before day 126 in each arm.
126 days after HCT
Proportion of correctors (i.e. patients reaching Hb > 12 g/dL) before day 126 in each arm.
126 days after HCT
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1NO_INTERVENTIONNo medication given
2ACTIVE_COMPARATORAranesp 300 µg/15 days
3ACTIVE_COMPARATORAranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.

Interventions

NameTypeDescription
Darbepoetin alpha (Aranesp)DRUGDarbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to \> 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
Iron saccharate (Venofer)DRUGIron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin \> 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS \> 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
Unlock Study Design Details

Eligibility Criteria

Age Range16 Years to 69 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion criteria: * Male or female; female patients must use a reliable contraception method * Age \> 16 yrs and \< 70 yrs * No terminal organ failure * Written informed consent given by patient or his/her guardian if of minor age. * Adequate iron stores (serum ferritin \> 100 µg/L) on day 21 pos...

Countries:Belgium
Unlock Eligibility Criteria